BeOne Medicines (ONC) Current Leases (2019 - 2026)

BeOne Medicines (ONC) has reported Current Leases for 8 consecutive years, with $22.0 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Current Leases rose 27.26% year-over-year to $22.0 million in Q2 2026; TTM through Jun 2026 was $22.0 million, a 27.26% increase from a year earlier, with the FY2025 full-year figure at $20.7 million, up 17.76% from the prior year.
• Current Leases was $22.0 million for Q2 2026 at BeOne Medicines, up from $20.6 million in the prior quarter.
• Over five years, Current Leases peaked at $24.8 million in Q2 2022 and troughed at $15.7 million in Q3 2025.
• A 5-year average of $20.9 million and a median of $21.3 million in 2023 frame the typical range for Current Leases.
• Across the five-year window, Current Leases surged 63.61% in 2022 and dropped 24.89% in 2024, its largest moves.
• Over 5 years, Current Leases stood at $24.0 million in 2022, then declined by 8.7% to $22.0 million in 2023, then declined by 19.93% to $17.6 million in 2024, then advanced by 17.76% to $20.7 million in 2025, then climbed by 6.06% to $22.0 million in 2026.
• The last three Current Leases figures came in at $22.0 million (Q2 2026), $20.6 million (Q1 2026), and $20.7 million (Q4 2025), per Business Quant data.